J
Jeffrey M. Beekman
Researcher at Utrecht University
Publications - 129
Citations - 7754
Jeffrey M. Beekman is an academic researcher from Utrecht University. The author has contributed to research in topics: Cystic fibrosis & Cystic fibrosis transmembrane conductance regulator. The author has an hindex of 36, co-authored 105 publications receiving 5848 citations. Previous affiliations of Jeffrey M. Beekman include University of Groningen & Medarex.
Papers
More filters
Journal ArticleDOI
Folding-function relationship of the most common cystic fibrosis-causing CFTR conductance mutants.
Marcel van Willigen,Annelotte M. Vonk,Hui Ying Yeoh,Evelien Kruisselbrink,Bertrand Kleizen,Cornelis K. van der Ent,Maarten R. Egmond,Hugo R. de Jonge,Ineke Braakman,Jeffrey M. Beekman,Peter van der Sluijs +10 more
TL;DR: This work revisited function and folding of some class-IV mutants and discovered that R347P is the only one that leads to major defects in folding, and qualifies also as a class-II mutation.
Journal ArticleDOI
Intestinal organoids to model Cystic Fibrosis
TL;DR: Organoid culture technologies are used to study hereditary diseases such as cystic fibrosis and more common diseases where genetics can influence disease severity and drug efficacy and drug testing in organoids could aid in finding drugs for people with rare CFTR mutations.
Journal ArticleDOI
β2-Adrenergic receptor agonists activate CFTR in intestinal organoids and subjects with cystic fibrosis
L.A.W. Vijftigschild,Gitte Berkers,Johanna F. Dekkers,Domenique D. Zomer-van Ommen,Elizabeth Matthes,Evelien Kruisselbrink,Annelotte M. Vonk,Chantal E Hensen,Sabine Heida-Michel,M. Geerdink,Hettie M. Janssens,Eduard A. van de Graaf,Inez Bronsveld,Karin M. de Winter-de Groot,Christof J. Majoor,Harry G.M. Heijerman,Hugo R. de Jonge,John W. Hanrahan,Cornelis K. van der Ent,Jeffrey M. Beekman +19 more
TL;DR: This proof-of-concept study suggests that organoids can be used to identify drugs that activate CFTR function in vivo and to select route of administration.
Journal ArticleDOI
R560S: A class II CFTR mutation that is not rescued by current modulators.
Nikhil T. Awatade,Sofia Ramalho,Iris A.L. Silva,Verónica Felício,Hugo M. Botelho,Eyleen de Poel,Annelotte M. Vonk,Jeffrey M. Beekman,Carlos M. Farinha,Margarida D. Amaral +9 more
TL;DR: The results indicate that R560S is a class II mutation, however, unlike F508del, it cannot be rescued by any of the CFTR modulators tested.
Journal ArticleDOI
Individualized medicine using intestinal responses to CFTR potentiators and correctors.
TL;DR: Recent advances concerning the use of intestinal biomarkers for CFTR modulator treatments are reviewed, with a focus on biomarkers of CFTR function in ex vivo rectal biopsies and in vitro cultured primary intestinal organoids.